GlassScriptPhysician profile
Francis Hsiao
NPI 1982855185
$64,617.75
in general payments reported to CMS, 2019-2025
45 companies · $13K in 2025
The $13K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,077 · 2020: $2,794 · 2021: $5,073 · 2022: $10K · 2023: $10K · 2024: $17K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $35K · Consulting Fee: $3,700 · Education: $526 · Travel and Lodging: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $35,208.13 |
| Consulting Fee | $3,700.00 |
| Education | $526.32 |
| Travel and Lodging | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $10,271.09 | 2019-2025 | Adbry, Anzupgo |
| Abbvie INC. | $9,846.41 | 2019-2025 | |
| Pfizer INC. | $4,959.21 | 2019-2025 | |
| Genzyme Corporation | $3,955.71 | 2019-2025 | |
| Janssen Biotech, INC. | $3,512.42 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| E.R. Squibb & Sons, L.L.C. | $3,349.60 | 2021-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $3,302.23 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $3,193.63 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Galderma Laboratories, L.P. | $3,065.61 | 2019-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $2,853.81 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $2,793.03 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $1,808.84 | 2020-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $1,701.52 | 2023-2025 | Zoryve |
| Incyte Corporation | $1,562.20 | 2021-2025 | Opzelura, Opzelura |
| Dermavant Sciences, INC. | $870.59 | 2022-2024 | Vtama |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $717.03 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $687.84 | 2019-2025 | Tremfya |
| Ucb, INC. | $681.46 | 2020-2025 | Bimzelx |
| Angiodynamics, INC. | $660.00 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $630.50 | 2019-2024 | Cabtreo, Arazlo, Jublia |
| Organogenesis INC. | $581.67 | 2021-2023 | Puraply |
| Almirall LLC | $406.23 | 2019-2025 | Klisyri |
| Vyne Pharmaceuticals INC. | $362.37 | 2020-2021 | |
| Celgene Corporation | $309.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.12 | 2022-2024 | Spevigo, Cyltezo |
| Mayne Pharma Commercial LLC | $223.18 | 2019-2020 | |
| Regeneron Pharmaceuticals, INC. | $219.46 | 2023-2024 | Dupixent |
| Dermira, INC. | $196.69 | 2019-2021 | |
| Allergan, INC. | $187.20 | 2019-2022 | |
| Sandoz INC. | $187.16 | 2019 | |
| Journey Medical Corporation | $186.76 | 2021-2025 | |
| Beigene USA, INC. | $149.66 | 2024 | Brukinsa |
| Genentech USA, INC. | $135.33 | 2022 | |
| Epi Health, LLC | $134.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $131.80 | 2021 | |
| Eli Lilly and Company | $119.25 | 2025 | Ebglyss |
| Nabriva Therapeutics, Plc | $94.81 | 2020-2021 | |
| Helsinn Therapeutics (U.S.), INC. | $87.19 | 2022 | |
| Convatec INC. | $63.15 | 2022-2023 | |
| Cipher Pharmaceuticals US LLC | $35.39 | 2025 | Natroba, Spinosad |
| Mimedx Group, INC. | $34.53 | 2024 | |
| Baudax Bio INC. | $20.96 | 2022 | |
| Strata Skin Sciences, INC. | $19.39 | 2023 | Xtrac |
| Biofrontera INC. | $15.18 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Smith+Nephew, INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Hsiao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.